MCID: PNC033
MIFTS: 66

Pancreas Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreas Adenocarcinoma

MalaCards integrated aliases for Pancreas Adenocarcinoma:

Name: Pancreas Adenocarcinoma 38 12
Pancreatic Adenocarcinoma 12 29 6 15
Adenocarcinoma of the Pancreas 12
Adenocarcinoma of Pancreas 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4074
NCIt 50 C8294
UMLS 73 C0281361

Summaries for Pancreas Adenocarcinoma

Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreas Adenocarcinoma, also known as pancreatic adenocarcinoma, is related to pancreatic cancer and adenocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreas Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abraxane and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include pancreas, t cells and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreas Adenocarcinoma

Diseases related to Pancreas Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 32.9 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
2 adenocarcinoma 31.3 AKT1 CDKN2A CTNNB1 ERBB2 GNAS HRAS
3 peutz-jeghers syndrome 30.6 CTNNB1 SMAD4 TP53
4 cystadenocarcinoma 30.3 AKT1 ERBB2 HRAS PIK3CA TP53
5 hepatocellular carcinoma 30.3 AKT1 CDKN2A CTNNB1 GNAS HRAS KRAS
6 lymphopenia 30.3 FOXP3 IFNG IL7
7 cholangiocarcinoma 30.2 AKT1 CTNNB1 ERBB2 KRAS MUC4 PIK3CA
8 sarcoma 30.2 CTNNB1 HRAS KRAS PIK3CA TP53
9 adenoma 30.2 CTNNB1 GNAS KRAS SMAD4 TP53
10 acinar cell carcinoma 30.2 CTNNB1 SMAD4 TP53
11 intrahepatic cholangiocarcinoma 30.2 CTNNB1 KRAS MUC4 TP53
12 ovarian cancer 30.2 AKT1 CTNNB1 ERBB2 ERCC1 KRAS PIK3CA
13 squamous cell carcinoma 30.1 AKT1 CDKN2A CTNNB1 ERBB2 HRAS PIK3CA
14 gastrointestinal stromal tumor 30.1 AKT1 CDKN2A KRAS TP53
15 cervical cancer 30.1 AKT1 CDKN2A CTNNB1 ERBB2 GNAS HRAS
16 esophageal cancer 30.1 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 HRAS
17 leukemia, chronic lymphocytic 2 30.1 HRAS KRAS TP53
18 colorectal cancer 30.1 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 GNAS
19 pancreatic ductal adenocarcinoma 11.4
20 acinar cell carcinoma of pancreas 11.2
21 pancreatic acinar cell adenocarcinoma 11.1
22 pancreatitis 10.5
23 adult hepatocellular carcinoma 10.5 CTNNB1 PIK3CA TP53
24 primary peritoneal carcinoma 10.5 ERBB2 ERCC1 IFNG TP53
25 mutyh-associated polyposis 10.5 KRAS SMAD4 TP53
26 apocrine adenoma 10.5 HRAS KRAS PIK3CA
27 rare adenocarcinoma of the breast 10.4 AKT1 KRAS PIK3CA TP53
28 gastrointestinal system benign neoplasm 10.4 CTNNB1 HRAS KRAS TP53
29 uterine corpus serous adenocarcinoma 10.4 ERBB2 PIK3CA TP53
30 intestinal benign neoplasm 10.4 CTNNB1 HRAS KRAS TP53
31 aggressive digital papillary adenocarcinoma 10.4 HRAS KRAS PIK3CA
32 nasal cavity adenocarcinoma 10.4 CDKN2A HRAS KRAS TP53
33 gallbladder adenoma 10.4 CDKN2A CTNNB1 HRAS
34 acneiform dermatitis 10.4 ERBB2 HRAS KRAS PIK3CA
35 spitz nevus 10.4 CDKN2A HRAS TP53
36 breast squamous cell carcinoma 10.4 ERBB2 PIK3CA TP53
37 adenosquamous lung carcinoma 10.4 ERBB2 HRAS KRAS PIK3CA
38 uterine body mixed cancer 10.4 ERBB2 PIK3CA TP53
39 anal canal adenocarcinoma 10.4 FOXP3 HRAS KRAS
40 upper respiratory tract disease 10.4 CDKN2A FOXP3 IFNG TP53
41 esophagus adenocarcinoma 10.4 ERBB2 SMAD4 TP53
42 anal squamous cell carcinoma 10.4 AKT1 CDKN2A PIK3CA TP53
43 lung adenoid cystic carcinoma 10.4 HRAS KRAS PIK3CA
44 bile duct adenocarcinoma 10.4 AKT1 HRAS KRAS TP53
45 appendix disease 10.4 GNAS HRAS KRAS
46 barrett's adenocarcinoma 10.4 CDKN2A ERBB2 KRAS TP53
47 ovary adenocarcinoma 10.4 ERBB2 HRAS KRAS PIK3CA TP53
48 colorectal adenoma 10.4 CTNNB1 HRAS KRAS TP53
49 colloid carcinoma of the pancreas 10.4 HRAS KRAS SMAD4
50 colorectal adenocarcinoma 10.4 CTNNB1 HRAS KRAS TP53

Graphical network of the top 20 diseases related to Pancreas Adenocarcinoma:



Diseases related to Pancreas Adenocarcinoma

Symptoms & Phenotypes for Pancreas Adenocarcinoma

UMLS symptoms related to Pancreas Adenocarcinoma:


abdominal pain, pruritus, icterus

GenomeRNAi Phenotypes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.27 HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.27 KRAS
3 Decreased viability GR00221-A-1 10.27 AKT1 CDKN2A HRAS KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.27 AKT1 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.27 AKT1 CDKN2A HRAS
6 Decreased viability GR00221-A-4 10.27 AKT1 CDKN2A PIK3CA
7 Decreased viability GR00301-A 10.27 KRAS
8 Decreased viability GR00381-A-1 10.27 KRAS
9 Decreased viability GR00402-S-2 10.27 AKT1 CDKN2A HRAS KRAS PIK3CA
10 Decreased cell migration GR00055-A-1 9.73 AKT1 CTNNB1 HRAS KRAS MAP2K2 PIK3CA
11 Decreased viability in esophageal squamous lineage GR00235-A 9.73 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3 GNAS
12 Increased cell migration GR00055-A-3 8.92 CTNNB1 HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Pancreas Adenocarcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.53 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
2 cellular MP:0005384 10.49 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
3 endocrine/exocrine gland MP:0005379 10.49 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
4 growth/size/body region MP:0005378 10.49 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
5 cardiovascular system MP:0005385 10.47 AKT1 CDKN2A CTNNB1 ERBB2 FOXP3 GNAS
6 homeostasis/metabolism MP:0005376 10.46 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
7 mortality/aging MP:0010768 10.4 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
8 immune system MP:0005387 10.39 AKT1 CDKN2A CTNNB1 ERCC1 FOXP3 GNAS
9 embryo MP:0005380 10.38 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 IFNG
10 hematopoietic system MP:0005397 10.38 AKT1 CDKN2A CTNNB1 ERCC1 FOXP3 GNAS
11 integument MP:0010771 10.38 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
12 craniofacial MP:0005382 10.35 CTNNB1 ERBB2 FOXP3 GNAS HRAS IFNG
13 digestive/alimentary MP:0005381 10.35 CDKN2A CTNNB1 ERBB2 FOXP3 HRAS IFNG
14 neoplasm MP:0002006 10.3 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 GNAS
15 nervous system MP:0003631 10.28 AKT1 CDKN2A CTNNB1 ERBB2 GNAS HRAS
16 liver/biliary system MP:0005370 10.25 AKT1 CDKN2A CTNNB1 ERCC1 FOXP3 GNAS
17 muscle MP:0005369 10.22 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 GNAS
18 adipose tissue MP:0005375 10.18 AKT1 ERCC1 GNAS MAP2K2 PIK3CA SLC29A1
19 limbs/digits/tail MP:0005371 10.18 CTNNB1 ERBB2 FOXP3 GNAS KRAS PTF1A
20 no phenotypic analysis MP:0003012 10.18 CDKN2A CTNNB1 FOXP3 GNAS HRAS IFNG
21 normal MP:0002873 10.15 AKT1 CTNNB1 ERBB2 FOXP3 GNAS HRAS
22 hearing/vestibular/ear MP:0005377 10.05 CTNNB1 FOXP3 GNAS KRAS MAP2K2 TP53
23 reproductive system MP:0005389 10 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 FOXP3
24 renal/urinary system MP:0005367 9.97 CTNNB1 ERCC1 FOXP3 GNAS HRAS IFNG
25 respiratory system MP:0005388 9.9 AKT1 CDKN2A CTNNB1 ERBB2 FOXP3 GNAS
26 skeleton MP:0005390 9.83 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1 GNAS
27 vision/eye MP:0005391 9.28 CDKN2A CTNNB1 FOXP3 IFNG KRAS MAP2K2

Drugs & Therapeutics for Pancreas Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Pancreas Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
4
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
5
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
6
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
7
Desflurane Approved Phase 4 57041-67-5 42113
8
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 1
21 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
22 Anesthetics Phase 4,Phase 2,Phase 1
23 Anesthetics, Inhalation Phase 4
24 Anesthetics, General Phase 4
25
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
26
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
27
leucovorin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
28
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
30
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
31
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
32
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 68538-85-2
33
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
34
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
35
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
36
Cetuximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 205923-56-4 56842117 2333
37
Epirubicin Approved Phase 2, Phase 3,Phase 1 56420-45-2 41867
38
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
39
Bevacizumab Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 216974-75-3
40
Dalteparin Approved Phase 3,Phase 2 9005-49-6
41
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
42
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
43 tannic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable
44
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
45
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
46
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
47
Ticlopidine Approved Phase 3 55142-85-3 5472
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-30-3 6037
49
Rubitecan Investigational Phase 3 91421-42-0
50
Camptothecin Experimental Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 7689-03-4

Interventional clinical trials:

(show top 50) (show all 748)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
2 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
3 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
5 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
6 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
7 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
8 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
9 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
11 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
12 PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Unknown status NCT00088660 Phase 3
13 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
14 Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
15 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
16 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
17 Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
18 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
19 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
20 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
21 Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
22 Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer Completed NCT00033735 Phase 3 fluorouracil;Irofulven
23 Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
24 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer Completed NCT00099294 Phase 3 Glufosfamide
25 Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
26 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
27 S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
28 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
29 Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
30 Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
31 Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
33 Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas Completed NCT00003029 Phase 3 cisplatin;fluorouracil
34 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
35 Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
36 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
37 Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
38 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
39 Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
40 Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
41 Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
42 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
43 Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
44 Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Recruiting NCT02072616 Phase 3
45 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
46 Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Recruiting NCT03504423 Phase 3 CPI 613, mFolfirinox;Folfirinox
47 EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Recruiting NCT03126435 Phase 3 EndoTAG-1;Gemcitabine
48 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Recruiting NCT01954992 Phase 3 Glufosfamide;Fluorouracil
49 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
50 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Recruiting NCT02184195 Phase 3 Olaparib;Olaparib;Placebo;Placebo

Search NIH Clinical Center for Pancreas Adenocarcinoma

Genetic Tests for Pancreas Adenocarcinoma

Genetic tests related to Pancreas Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29

Anatomical Context for Pancreas Adenocarcinoma

MalaCards organs/tissues related to Pancreas Adenocarcinoma:

41
Pancreas, T Cells, Endothelial, Lymph Node, Liver, Testes, Bone

Publications for Pancreas Adenocarcinoma

Articles related to Pancreas Adenocarcinoma:

(show top 50) (show all 1450)
# Title Authors Year
1
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
2
Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. ( 29452076 )
2018
3
A Rare Multifocal Pattern of Type 2 Autoimmune Pancreatitis with Negative IgG4: A Potential Diagnostic Pitfall That May Mimic Multifocal Pancreatic Adenocarcinoma. ( 29681791 )
2018
4
Inhibition of CX<sub>3</sub>CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. ( 29274778 )
2018
5
Paraneoplastic Stiff Person Syndrome Secondary to Pancreatic Adenocarcinoma. ( 29110193 )
2018
6
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. ( 29599352 )
2018
7
Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. ( 29448308 )
2018
8
Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: novel imaging findings for differentiation from pancreatic adenocarcinoma. ( 29948059 )
2018
9
The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. ( 29033025 )
2018
10
Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. ( 30522947 )
2018
11
Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. ( 30524902 )
2018
12
Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival. ( 30537722 )
2018
13
First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. ( 30538546 )
2018
14
Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. ( 30539487 )
2018
15
Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. ( 30539680 )
2018
16
First reported case of a collision tumor composed of pancreatic adenocarcinoma and retroperitoneal liposarcoma: a case report. ( 30541485 )
2018
17
Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. ( 30545994 )
2018
18
Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. ( 30551868 )
2018
19
LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. ( 30556854 )
2018
20
How hsa-miR-495 performed in the tumorigenesis of pancreatic adenocarcinoma by bioinformatics analysis. ( 30485500 )
2018
21
Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma. ( 30498448 )
2018
22
Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. ( 30501986 )
2018
23
Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? ( 30501987 )
2018
24
Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX. ( 30505579 )
2018
25
Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. ( 30506016 )
2018
26
RET, a Targetable Driver of Pancreatic Adenocarcinoma. ( 30515799 )
2018
27
CT perfusion and diffusion-weighted MR imaging of pancreatic adenocarcinoma: can we predict tumor grade using functional parameters? ( 30428264 )
2018
28
ASO Author Reflections: Staging Laparoscopy Improves Overall Survival of Patients with Pancreatic Adenocarcinoma Found to Have Occult Metastatic Disease. ( 30430323 )
2018
29
Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. ( 30449481 )
2018
30
The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. ( 30449494 )
2018
31
Socioeconomic status impacts survival and access to resection in pancreatic adenocarcinoma: A high-resolution population-based cancer registry study. ( 30449504 )
2018
32
Amenorrhea along with renal and thyroid metastasis: Unusual presentation of pancreatic adenocarcinoma. ( 30449933 )
2018
33
CLPTM1L/CRR9 Ectodomain Interaction with GRP78 at the Cell Surface Signals for Survival and Chemoresistance upon ER Stress in Pancreatic Adenocarcinoma Cells. ( 30468251 )
2018
34
Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. ( 30477242 )
2018
35
Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. ( 30380143 )
2018
36
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. ( 30391013 )
2018
37
Diffuse Large B-Cell Lymphoma With Striking Intrasinusoidal Pseudoglandular Growth Pattern as a Diagnostic Dilemma Mimicking Metastatic Poorly Differentiated Pancreatic Adenocarcinoma in an Intraabdominal Lymph Node. ( 30392418 )
2018
38
A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts. ( 30404163 )
2018
39
Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. ( 30406031 )
2018
40
Barriers to Surgical Resection of Pancreatic Adenocarcinoma. ( 30406483 )
2018
41
Ubiquitin-independent, Proteasome-mediated targeted degradation of KRAS in pancreatic adenocarcinoma cells using an engineered ornithine decarboxylase/antizyme system. ( 30347501 )
2018
42
Impact of Ethnicity on Somatic Mutation Rates of Pancreatic Adenocarcinoma. ( 30348712 )
2018
43
Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China. ( 30349376 )
2018
44
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. ( 30362063 )
2018
45
Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. ( 30373552 )
2018
46
Intraoperative radiotherapy with the Intrabeam® device for the treatment of resectable pancreatic adenocarcinoma. ( 30297032 )
2018
47
Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. ( 30298281 )
2018
48
Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma. ( 30309212 )
2018
49
Screening to Detect Precursor Lesions of Pancreatic Adenocarcinoma in High-risk Individuals: A Single-center Experience. ( 30309438 )
2018
50
Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III? ( 30326370 )
2018

Variations for Pancreas Adenocarcinoma

ClinVar genetic disease variations for Pancreas Adenocarcinoma:

6 (show top 50) (show all 784)
# Gene Variation Type Significance SNP ID Assembly Location
1 PALLD NM_001166110.1(PALLD): c.415C> T (p.Pro139Ser) single nucleotide variant risk factor rs121908291 GRCh37 Chromosome 4, 169799457: 169799457
2 PALLD NM_001166110.1(PALLD): c.415C> T (p.Pro139Ser) single nucleotide variant risk factor rs121908291 GRCh38 Chromosome 4, 168878306: 168878306
3 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
4 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
5 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
6 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
7 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
8 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
9 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
10 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
11 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
12 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
13 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
14 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
15 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
16 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
17 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
18 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
19 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
20 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
21 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
22 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
23 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
24 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
26 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
27 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
28 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
29 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
30 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
31 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
32 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
33 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
34 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
35 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
36 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
37 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
38 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
39 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
40 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
41 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
42 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
43 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
44 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
45 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
46 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
47 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
48 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
49 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
50 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092

Cosmic variations for Pancreas Adenocarcinoma:

9 (show top 50) (show all 3007)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5575790 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 8
2 COSM5576102 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 8
3 COSM5576231 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 8
4 COSM5575704 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 8
5 COSM5576098 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 8
6 COSM3732832 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 8
7 COSM6964818 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 8
8 COSM6953000 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 8
9 COSM6965918 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 8
10 COSM6826469 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 8
11 COSM6941990 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 8
12 COSM6986594 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 8
13 COSM6934198 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 8
14 COSM6944960 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 8
15 COSM6951579 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 8
16 COSM5576197 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 8
17 COSM185632 WT1 stomach,NS,carcinoma,adenocarcinoma c.869C>T p.T290M 11:32399973-32399973 8
18 COSM926359 WT1 stomach,NS,carcinoma,adenocarcinoma c.1298G>A p.R433H 11:32389110-32389110 8
19 COSM6906958 WT1 stomach,NS,carcinoma,adenocarcinoma c.122C>T p.A41V 11:32435020-32435020 8
20 COSM20570 WEE2 stomach,NS,carcinoma,adenocarcinoma c.996C>G p.N332K 7:141723249-141723249 8
21 COSM3732971 USH2A stomach,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 1:215878834-215878834 8
22 COSM3732707 USH2A stomach,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 1:216422197-216422197 8
23 COSM3732771 USH2A stomach,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 1:215728281-215728281 8
24 COSM3732767 USH2A stomach,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 1:215728362-215728362 8
25 COSM3732855 USH2A stomach,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 1:215728169-215728169 8
26 COSM1094394 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5561G>A p.R1854H 8:102285262-102285262 8
27 COSM5575712 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5261G>A p.R1754Q 8:102285736-102285736 8
28 COSM6928622 U2AF1 stomach,NS,carcinoma,adenocarcinoma c.68A>G p.K23R 21:43104379-43104379 8
29 COSM3793896 TSHR stomach,NS,carcinoma,adenocarcinoma c.909G>C p.E303D 14:81142967-81142967 8
30 COSM6949448 TSHR stomach,NS,carcinoma,adenocarcinoma c.256G>A p.D86N 14:81068267-81068267 8
31 COSM6505728 TSC2 stomach,NS,carcinoma,adenocarcinoma c.5377C>T p.R1793W 16:2088563-2088563 8
32 COSM5576247 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2803G>T p.A935S 16:2076551-2076551 8
33 COSM6922577 TSC2 stomach,NS,carcinoma,adenocarcinoma c.3820T>C p.S1274P 16:2082441-2082441 8
34 COSM5575753 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2357G>A p.R786H 16:2074201-2074201 8
35 COSM6921200 TSC2 stomach,NS,carcinoma,adenocarcinoma c.445A>G p.N149D 16:2054404-2054404 8
36 COSM6915776 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2066G>A p.R689H 9:132903793-132903793 8
37 COSM6963024 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2161C>T p.R721C 9:132903698-132903698 8
38 COSM5576069 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2143C>T p.R715W 9:132903716-132903716 8
39 COSM6924108 TSC1 stomach,NS,carcinoma,adenocarcinoma c.3185G>A p.R1062Q 9:132896545-132896545 8
40 COSM6952020 TSC1 stomach,NS,carcinoma,adenocarcinoma c.941C>T p.T314M 9:132911541-132911541 8
41 COSM6915052 TSC1 stomach,NS,carcinoma,adenocarcinoma c.1906G>A p.E636K 9:132905672-132905672 8
42 COSM5575742 TRRAP stomach,NS,carcinoma,adenocarcinoma c.622G>A p.E208K 7:98897855-98897855 8
43 COSM20551 TRRAP stomach,NS,carcinoma,adenocarcinoma c.5117G>A p.R1706H 7:98950120-98950120 8
44 COSM2866680 TRRAP stomach,NS,carcinoma,adenocarcinoma c.5956C>T p.R1986W 7:98956239-98956239 8
45 COSM5575878 TRRAP stomach,NS,carcinoma,adenocarcinoma c.10447G>A p.A3483T 7:99005171-99005171 8
46 COSM20550 TRRAP stomach,NS,carcinoma,adenocarcinoma c.477A>G p.K159K 7:98895790-98895790 8
47 COSM5576201 TRRAP stomach,NS,carcinoma,adenocarcinoma c.2075A>G p.Y692C 7:98912089-98912089 8
48 COSM5576203 TRRAP stomach,NS,carcinoma,adenocarcinoma c.8165C>T p.P2722L 7:98976763-98976763 8
49 COSM20561 TRPM7 stomach,NS,carcinoma,adenocarcinoma c.2488A>G p.M830V 15:50609673-50609673 8
50 COSM1542406 TRIO stomach,NS,carcinoma,adenocarcinoma c.6611A>G p.K2204R 5:14482727-14482727 8

Expression for Pancreas Adenocarcinoma

Search GEO for disease gene expression data for Pancreas Adenocarcinoma.

Pathways for Pancreas Adenocarcinoma

Pathways related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 171)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 AKT1 CTNNB1 ERBB2 HRAS IFNG IL7
2
Show member pathways
14 AKT1 CDKN2A CTNNB1 ERBB2 GNAS HRAS
3
Show member pathways
13.85 AKT1 CDKN2A ERBB2 GNAS HRAS KRAS
4
Show member pathways
13.84 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
5
Show member pathways
13.83 AKT1 ERBB2 GNAS HRAS IFNG IL7
6
Show member pathways
13.68 AKT1 CTNNB1 ERBB2 GNAS HRAS KRAS
7
Show member pathways
13.68 AKT1 ERBB2 GNAS HRAS IFNG IL7
8
Show member pathways
13.65 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
9
Show member pathways
13.52 AKT1 ERBB2 HRAS IFNG IL7 KRAS
10
Show member pathways
13.42 AKT1 CTNNB1 ERBB2 HRAS IL7 KRAS
11
Show member pathways
13.41 AKT1 CTNNB1 ERBB2 GNAS HRAS KRAS
12
Show member pathways
13.36 AKT1 ERBB2 GNAS HRAS IFNG KRAS
13
Show member pathways
13.19 AKT1 GNAS HRAS KRAS MAP2K2 TP53
14
Show member pathways
13.19 AKT1 CDKN2A CTNNB1 GNAS HRAS KRAS
15
Show member pathways
13.19 AKT1 CDKN2A CTNNB1 GNAS HRAS KRAS
16
Show member pathways
13.17 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
17
Show member pathways
13.16 AKT1 GNAS HRAS KRAS MAP2K2 PIK3CA
18
Show member pathways
13.13 AKT1 CTNNB1 ERBB2 GNAS HRAS IL7
19
Show member pathways
13.11 AKT1 CTNNB1 HRAS KRAS MAP2K2 PIK3CA
20
Show member pathways
13.08 AKT1 GNAS HRAS KRAS MAP2K2 PIK3CA
21
Show member pathways
13.06 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
22
Show member pathways
13.04 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
23
Show member pathways
13.03 AKT1 ERBB2 GNAS HRAS KRAS MAP2K2
24
Show member pathways
12.98 AKT1 CDKN2A HRAS KRAS MAP2K2 PIK3CA
25
Show member pathways
12.96 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
26
Show member pathways
12.94 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
27
Show member pathways
12.93 AKT1 HRAS IL7 KRAS MAP2K2 PIK3CA
28 12.92 AKT1 ERBB2 HRAS KRAS MAP2K2 TP53
29
Show member pathways
12.92 AKT1 CDKN2A ERBB2 GNAS HRAS KRAS
30
Show member pathways
12.91 AKT1 IFNG MAP2K2 PIK3CA TP53
31
Show member pathways
12.9 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
32
Show member pathways
12.89 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
33
Show member pathways
12.88 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
34
Show member pathways
12.85 AKT1 GNAS HRAS KRAS MAP2K2
35
Show member pathways
12.84 AKT1 HRAS IFNG KRAS MAP2K2 TP53
36
Show member pathways
12.84 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
37
Show member pathways
12.8 AKT1 GNAS HRAS KRAS MAP2K2
38
Show member pathways
12.76 AKT1 HRAS IFNG MAP2K2 PIK3CA
39
Show member pathways
12.75 AKT1 CTNNB1 ERBB2 HRAS IFNG KRAS
40
Show member pathways
12.73 AKT1 HRAS KRAS MAP2K2 PIK3CA
41
Show member pathways
12.73 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
42
Show member pathways
12.71 AKT1 GNAS HRAS MAP2K2 PIK3CA
43 12.7 CDKN2A ERBB2 HRAS KRAS MAP2K2 PIK3CA
44
Show member pathways
12.68 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
45
Show member pathways
12.67 HRAS IFNG KRAS MAP2K2 PIK3CA
46
Show member pathways
12.66 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
47
Show member pathways
12.66 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
48
Show member pathways
12.61 AKT1 HRAS IFNG KRAS MAP2K2 PIK3CA
49
Show member pathways
12.6 AKT1 HRAS KRAS MAP2K2 PIK3CA
50
Show member pathways
12.6 CDKN2A CTNNB1 GNAS HRAS KRAS MAP2K2

GO Terms for Pancreas Adenocarcinoma

Cellular components related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.8 AKR7A3 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1
2 intracellular GO:0005622 9.76 AKT1 CTNNB1 FOXP3 IFNG PIK3CA PTF1A
3 cytoplasm GO:0005737 9.53 AKR7A3 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1

Biological processes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.99 CDKN2A CTNNB1 FOXP3 IFNG SMAD4 TP53
2 positive regulation of cell proliferation GO:0008284 9.97 AKT1 CTNNB1 HRAS IFNG IL7 KRAS
3 MAPK cascade GO:0000165 9.91 ERBB2 HRAS KRAS MAP2K2
4 cytokine-mediated signaling pathway GO:0019221 9.88 AKT1 IL7 KRAS PIK3CA TP53
5 negative regulation of cell proliferation GO:0008285 9.88 CDKN2A CTNNB1 FOXP3 HRAS SMAD4 TP53
6 cell cycle arrest GO:0007050 9.83 CDKN2A HRAS IFNG TP53
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.77 HRAS KRAS MUC4
8 positive regulation of protein phosphorylation GO:0001934 9.77 AKT1 ERBB2 HRAS IFNG KRAS
9 positive regulation of MAP kinase activity GO:0043406 9.76 ERBB2 HRAS KRAS
10 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 CDKN2A CTNNB1 FOXP3 MAP2K2 PTF1A
11 cellular response to growth factor stimulus GO:0071363 9.74 AKT1 CTNNB1 ERBB2
12 negative regulation of gene expression GO:0010629 9.73 AKT1 CTNNB1 FOXP3 HRAS IFNG MAP2K2
13 negative regulation of interleukin-17 production GO:0032700 9.63 FOXP3 IFNG
14 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 AKT1 ERBB2 PIK3CA
15 positive regulation of organ growth GO:0046622 9.62 AKT1 IL7
16 anoikis GO:0043276 9.62 AKT1 PIK3CA
17 Ras protein signal transduction GO:0007265 9.62 CDKN2A HRAS KRAS TP53
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 MAP2K2 TP53
19 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.6 CDKN2A IFNG
20 response to isolation stress GO:0035900 9.58 HRAS KRAS
21 positive regulation of core promoter binding GO:1904798 9.56 CTNNB1 IFNG
22 hair follicle placode formation GO:0060789 9.55 CTNNB1 GNAS
23 negative regulation of immature T cell proliferation in thymus GO:0033088 9.54 CDKN2A ERBB2
24 cell proliferation GO:0008283 9.5 AKT1 CTNNB1 ERBB2 ERCC1 HRAS SMAD4
25 positive regulation of gene expression GO:0010628 9.28 AKT1 CDKN2A CTNNB1 ERBB2 FOXP3 HRAS
26 positive regulation of transcription by RNA polymerase II GO:0045944 10.03 AKT1 CDKN2A CTNNB1 FOXP3 HRAS PTF1A

Molecular functions related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.61 CTNNB1 ERBB2 TP53
2 protein C-terminus binding GO:0008022 9.56 CTNNB1 ERBB2 ERCC1 HRAS
3 nucleotide binding GO:0000166 9.55 AKT1 ERBB2 HRAS KRAS MAP2K2
4 I-SMAD binding GO:0070411 9.4 CTNNB1 SMAD4
5 TFIID-class transcription factor complex binding GO:0001094 9.37 ERCC1 TP53
6 RNA polymerase II transcription factor binding GO:0001085 9.13 CTNNB1 SMAD4 TP53
7 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53
8 protein binding GO:0005515 10.25 AKR7A3 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1

Sources for Pancreas Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....